STOCK TITAN

Vycor Medical (VYCO) Stock Price, News & Analysis

VYCO OTC
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
36 79 sessions, November 3, 2025 to October 28, 2026
Largest daily move
+49.7% close of October 28, 2026

Company Description

Vycor Medical, Inc. (VYCO) is a corporation organized in the state of Delaware and subject to the reporting requirements of the Securities Exchange Act of 1934. The company files periodic and current reports with the U.S. Securities and Exchange Commission (SEC) under Commission File Number 001-34932 and federal tax identification number 20-3369218, as disclosed in its Form 8-K filing.

According to a Form 8-K dated November 14, 2025, Vycor Medical, Inc. reported information related to its results of operations and financial condition for the three- and nine-month periods ended September 30, 2025. This information was furnished under Item 2.02 of Form 8-K, which covers results of operations and financial condition. The filing specifies that the information provided under this item, and the related exhibit, is furnished rather than filed for purposes of Section 18 of the Exchange Act.

The same Form 8-K notes that Vycor Medical, Inc. issued a press release on November 14, 2025, discussing its financial results for the referenced periods. That press release is identified as Exhibit 99.1 to the Form 8-K. The company indicates that it uses both GAAP and non-GAAP financial measures when discussing its operating performance.

Use of Non-GAAP Financial Measures

In the Form 8-K, Vycor Medical, Inc. explains that it makes reference to non-GAAP financial information in its press release. Specifically, the company identifies non-GAAP Cash Operating Expenses and non-GAAP Cash Operating Loss measures. These non-GAAP measures exclude depreciation and non-cash stock compensation from the comparable GAAP financial measures.

The company states that management uses these non-GAAP measures to conduct what it considers a more meaningful and consistent comparison of ongoing operating results and trends, both against historical periods and against internally developed targets. Vycor Medical, Inc. also acknowledges that non-GAAP financial measures have limitations, including that they are not prepared in accordance with GAAP and may differ from similarly titled measures used by other companies.

The Form 8-K emphasizes that investors and potential investors should consider the non-GAAP financial measures only together with the company’s consolidated financial statements prepared in accordance with GAAP, as well as the reconciliations of non-GAAP to GAAP measures provided in the press release.

Regulatory Reporting and Investor Information

Vycor Medical, Inc. provides its financial information to the market through SEC filings, including current reports on Form 8-K. The November 14, 2025 Form 8-K illustrates how the company communicates quarterly financial results and the way it supplements GAAP results with non-GAAP metrics. The filing also includes an Exhibit 104 reference for the cover page interactive data file embedded within the Inline XBRL document, which is part of the SEC’s structured data requirements.

Because the available information is drawn from a specific Form 8-K, detailed descriptions of the company’s industry, products, services, and business model are not provided in that filing. Investors seeking a fuller understanding of Vycor Medical, Inc.’s operations typically review its annual reports on Form 10-K, quarterly reports on Form 10-Q, and additional current reports on Form 8-K, along with any related exhibits that discuss its activities in more detail.

Summary of Available Public Information

Based on the referenced Form 8-K, Vycor Medical, Inc. can be characterized as:

  • A Delaware corporation that files reports with the SEC under File Number 001-34932.
  • A company that communicates financial results through press releases furnished as exhibits to Form 8-K.
  • An issuer that uses both GAAP and specified non-GAAP financial measures, including non-GAAP Cash Operating Expenses and non-GAAP Cash Operating Loss, with reconciliations provided in its press releases.
  • An SEC registrant that presents interactive data for its cover page through Inline XBRL, as indicated by Exhibit 104.

Further details about its sector, industry classification, and specific business activities are not contained in the provided Form 8-K excerpt and would need to be obtained from other SEC filings or company disclosures.

Stock Performance

$0.0524
+49.71%
+0.0174
Last updated: October 28, 2026 at 16:00
+54.1%
Performance 1 week

Vycor Medical (VYCO) closed at $0.0524 on October 28, 2026. Over the past week, the price has gained 54.1%.

See what a $1,000 investment in VYCO would be worth today

Average down calculator for VYCO

VYCO Metrics & Rankings

Market Cap
$1.7M
View ranking

Price returns through October 28, 2026. Ranking links may use different dates.

Latest News

No recent news available for VYCO.

Financial Highlights

Vycor Medical generated $1.9M in revenue in FY2025, retaining a 83.8% gross margin, operating income reached $34K (1.8% operating margin), and net income was -$72K, reflecting a -3.9% net profit margin. Diluted earnings per share stood at -$0.01. The company generated -$13K in operating cash flow. The current ratio was 0.12, measuring current assets divided by current liabilities.

$1.9M
Revenue (FY2025)
-$72K
Net Income (FY2025)
-$13K
Operating Cash Flow

Upcoming Events

No upcoming events scheduled for VYCO.

Short Interest History

Last 12 Months

Short interest in Vycor Medical (VYCO) currently stands at 12.1 thousand shares, representing 0.1% of the float. Since November 2025, short interest has increased by 539.5%.

Days to Cover History

Last 12 Months

Days to cover for Vycor Medical (VYCO) currently stands at 1000.0 days. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 99899%. Across the settlements charted above, it has ranged from 1.0 to 1000.0 days.

VYCO Company Profile & Sector Positioning

Vycor Medical (VYCO) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the OTC.

Investors comparing VYCO often look at related companies in the same sector, including CS Diagnostics Corp (CSDX), Therma Bright Inc (TBRIF), Biotricity Inc (BTCY), REMSleep Holdings Inc (RMSL), and Odyssey Health Inc (ODYY). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate VYCO's relative position within its industry.

Frequently Asked Questions

The current stock price of Vycor Medical (VYCO) is $0.0524 as of October 28, 2026.

The market cap of Vycor Medical (VYCO) is approximately $1.7M. Learn more about what market capitalization means .

The FY2025 revenue of Vycor Medical (VYCO) is $1.9M, from its most recent completed fiscal year.

The FY2025 net income of Vycor Medical (VYCO) is -$72K, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Vycor Medical (VYCO) is -$0.01 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Vycor Medical (VYCO) is -$13K for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Vycor Medical (VYCO) is -3.9% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Vycor Medical (VYCO) is 1.8% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Vycor Medical (VYCO) is 83.8% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Vycor Medical (VYCO), current assets divided by current liabilities, was 0.12 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Vycor Medical (VYCO) is $1.6M for FY2025, its most recent completed fiscal year.

The operating income of Vycor Medical (VYCO) is $34K for FY2025, its most recent completed fiscal year. Learn about operating income.

Vycor Medical, Inc. is a Delaware corporation that files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-34932, as disclosed in its Form 8-K.

Vycor Medical, Inc. is associated with the stock symbol VYCO, which is used on Stock Titan to reference the company and its SEC reporting history.

On November 14, 2025, Vycor Medical, Inc. furnished a Form 8-K under Item 2.02 to provide information about its results of operations and financial condition for the three and nine months ended September 30, 2025.

In its Form 8-K, Vycor Medical, Inc. explains that it uses non-GAAP financial measures such as non-GAAP Cash Operating Expenses and non-GAAP Cash Operating Loss, which exclude depreciation and non-cash stock compensation from the comparable GAAP measures.

Vycor Medical, Inc. states that management uses non-GAAP metrics to conduct what it views as a more meaningful and consistent comparison of ongoing operating results and trends against historical periods and internal targets, while acknowledging the limitations of non-GAAP measures.

According to the Form 8-K, reconciliations of Vycor Medical, Inc.’s non-GAAP financial measures to the most directly comparable GAAP measures are provided in the press release furnished as Exhibit 99.1.

Exhibit 99.1 to the Form 8-K dated November 14, 2025 is a press release from Vycor Medical, Inc. that discusses its financial results for the three and nine months ended September 30, 2025.

Exhibit 104 in the Form 8-K refers to the cover page interactive data file, which is embedded within the Inline XBRL document as part of the SEC’s structured data requirements.

The Form 8-K specifies that the information in the report and the attached exhibit are furnished under Item 2.02 and are not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, except as may be expressly incorporated by reference elsewhere.

The press release furnished as Exhibit 99.1 to the Form 8-K dated November 14, 2025 covers Vycor Medical, Inc.’s financial results for the three and nine months ended September 30, 2025.